[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letter-tianjin-healthcare-medical-technology-co-ltd-736415-10292026":3,"fda-latest-sync-dates":30},{"id":4,"letter_id":5,"action_type":6,"firm_name":7,"fei_number":8,"issuing_office":9,"subject":10,"posted_date":11,"action_taken_date":12,"response_letter_date":8,"closeout_date":8,"case_status":13,"letter_url":14,"reference_number":15,"marcs_cms_no":16,"product_type":17,"delivery_method":18,"recipient_name":19,"recipient_title":8,"body_html":20,"body_text":21,"body_fetched_at":22,"medical_device_id":8,"raw":23,"created_at":28,"updated_at":29},22203,"tianjin-healthcare-medical-technology-co-ltd-736415-10292026","Warning Letter","Tianjin Healthcare Medical Technology Co., Ltd.",null,"Center for Drug Evaluation and Research (CDER)","Refusal to Provide Access to and Copying of Records","2026-11-10","2026-10-29","Issued","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftianjin-healthcare-medical-technology-co-ltd-736415-10292026","320-27-15","736415","Drugs Over-the-Counter Drugs","VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","Jianyu Zhao","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-27-15\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jianyu Zhao\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Firm Contact\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Tianjin Healthcare Medical Technology Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2-2066, No 88 HuanHe South Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Tianjin Free Trade Pilot Zone\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>KongGang Economic Zone\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Tianjin Shi\u003C\u002Fspan>, \u003Cspan>300000\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 29, 2026\u003Cbr>&nbsp;\u003C\u002Fp>\u003Cp>WARNING LETTER\u003Cbr>Reference number: 320-27-15\u003C\u002Fp>\u003Cp>To Jianyu Zhao:\u003C\u002Fp>\u003Cp>This warning letter advises you of a significant violation identified during a U.S. Food and Drug Administration (FDA) review of records from your facility and provides you the opportunity to address them. This is not intended to be an all-inclusive list of violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory action without further notice.\u003C\u002Fp>\u003Cp>Your facility, Tianjin Healthcare Medical Technology Co., Ltd. (hereafter THM), FDA Establishment Identifier (FEI) # 3015495180 at 2-2066, No 88 HuanHe South Road, Tianjin Free Trade Pilot Zone, KongGang Economic Zone, Tianjin is registered with the FDA as a manufacturer of active pharmaceutical ingredients (APIs).\u003C\u002Fp>\u003Cp>A review of import records showed multiple shipments of APIs intended for pharmacy compounding into the U.S., which declared THM, as the drug manufacturer. The FDA sent requests for records and other information, pursuant to section 704(a)(4) of the Federal Food, Drug and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 374(a)(4), to the contact email address provided in your registration file. Your firm refused to provide the duly requested records.\u003C\u002Fp>\u003Cp>It is a prohibited act under section 301(e) of the FD&amp;C Act (21 U.S.C. 331(e)) to refuse to permit access to or copying of any record as required by section 704(a). Because your firm failed to respond to the section 704(a)(4) records requests and associated communication attempts, we have no indication of the level of quality assurance for drugs listed as manufactured at your facility.\u003C\u002Fp>\u003Cp>\u003Cstrong>Refusal to Provide Records\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>On June 17, 2026, the FDA sent an electronic records request to the contact email address provided in your registration file. You replied on June 24, 2026, that you would “discontinue the production of relevant \u003Cstrong>(b)(4)\u003C\u002Fstrong> products” for the U.S. market and refused to provide the requested documents. A follow up request was sent on June 25, 2026, informing you that APIs your firm manufactured were imported to the U.S. market and were still within expiry. Therefore, the requested records were still required. You responded that you would not provide the requested records.\u003C\u002Fp>\u003Cp>Simply ceasing commercial distribution or expressing an intent to stop production does not retroactively relieve you of your regulatory obligations.\u003C\u002Fp>\u003Cp>FDA placed all drugs and drug products offered for import into the U.S. from your firm on Import Alert 66-79 on August 25, 2026.\u003C\u002Fp>\u003Cp>If you no longer intend to manufacture or distribute drug products for the U.S. market, you must formally update your registration and drug listings to reflect this change in operations. Pursuant to 21 CFR 207.29(a)(3), an establishment must update its registration within 30 calendar days of ceasing operations.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violation cited in this letter is not intended to be an all-inclusive list of violations at your facility.\u003C\u002Fp>\u003Cp>Until FDA is able to confirm compliance with CGMP and other applicable requirements, we may withhold approval of any new applications or supplements listing your firm as a drug manufacturer. In addition, shipments of articles manufactured at THM, 2-2066, No 88 HuanHe South Road, Tianjin Free Trade Pilot Zone, KongGang Economic Zone, Tianjin into the U.S. that appear to be adulterated or misbranded are subject to being detained or refused admission pursuant to section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3).\u003C\u002Fp>\u003Cp>In response to this letter, you may submit a request to schedule an FDA inspection.\u003C\u002Fp>\u003Cp>Send your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with FEI 3015495180 and ATTN: Marva Taylor in the letter in the subject line of the email.\u003C\u002Fp>\u003Cp>If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration.\u003C\u002Fp>\u003Cp>FDA posts warning letters to www.FDA.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>cc: U.S. agent\u003Cbr>\u003Cstrong>(b)(6)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nReference #:\n\n320-27-15\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nJianyu Zhao\n\nRecipient Title\n\nFirm Contact\n\nTianjin Healthcare Medical Technology Co., Ltd.\n\n2-2066, No 88 HuanHe South Road\n\nTianjin Free Trade Pilot Zone\n\nKongGang Economic Zone\n\nTianjin Shi, 300000\n\nChina\n\n(b)(6)\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nOctober 29, 2026\n\nWARNING LETTER\nReference number: 320-27-15\nTo Jianyu Zhao:\nThis warning letter advises you of a significant violation identified during a U.S. Food and Drug Administration (FDA) review of records from your facility and provides you the opportunity to address them. This is not intended to be an all-inclusive list of violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory action without further notice.\nYour facility, Tianjin Healthcare Medical Technology Co., Ltd. (hereafter THM), FDA Establishment Identifier (FEI) # 3015495180 at 2-2066, No 88 HuanHe South Road, Tianjin Free Trade Pilot Zone, KongGang Economic Zone, Tianjin is registered with the FDA as a manufacturer of active pharmaceutical ingredients (APIs).\nA review of import records showed multiple shipments of APIs intended for pharmacy compounding into the U.S., which declared THM, as the drug manufacturer. The FDA sent requests for records and other information, pursuant to section 704(a)(4) of the Federal Food, Drug and Cosmetic Act (FD&C Act), 21 U.S.C. 374(a)(4), to the contact email address provided in your registration file. Your firm refused to provide the duly requested records.\nIt is a prohibited act under section 301(e) of the FD&C Act (21 U.S.C. 331(e)) to refuse to permit access to or copying of any record as required by section 704(a). Because your firm failed to respond to the section 704(a)(4) records requests and associated communication attempts, we have no indication of the level of quality assurance for drugs listed as manufactured at your facility.\nRefusal to Provide Records\nOn June 17, 2026, the FDA sent an electronic records request to the contact email address provided in your registration file. You replied on June 24, 2026, that you would “discontinue the production of relevant (b)(4) products” for the U.S. market and refused to provide the requested documents. A follow up request was sent on June 25, 2026, informing you that APIs your firm manufactured were imported to the U.S. market and were still within expiry. Therefore, the requested records were still required. You responded that you would not provide the requested records.\nSimply ceasing commercial distribution or expressing an intent to stop production does not retroactively relieve you of your regulatory obligations.\nFDA placed all drugs and drug products offered for import into the U.S. from your firm on Import Alert 66-79 on August 25, 2026.\nIf you no longer intend to manufacture or distribute drug products for the U.S. market, you must formally update your registration and drug listings to reflect this change in operations. Pursuant to 21 CFR 207.29(a)(3), an establishment must update its registration within 30 calendar days of ceasing operations.\nConclusion\nThe violation cited in this letter is not intended to be an all-inclusive list of violations at your facility.\nUntil FDA is able to confirm compliance with CGMP and other applicable requirements, we may withhold approval of any new applications or supplements listing your firm as a drug manufacturer. In addition, shipments of articles manufactured at THM, 2-2066, No 88 HuanHe South Road, Tianjin Free Trade Pilot Zone, KongGang Economic Zone, Tianjin into the U.S. that appear to be adulterated or misbranded are subject to being detained or refused admission pursuant to section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3).\nIn response to this letter, you may submit a request to schedule an FDA inspection.\nSend your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with FEI 3015495180 and ATTN: Marva Taylor in the letter in the subject line of the email.\nIf you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.\nFDA posts warning letters to www.FDA.gov.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\ncc: U.S. agent\n(b)(6)","2026-11-17T01:02:49.249+00:00",[24,25,26,9,10,27,27,27],"\u003Ctime datetime=\"2026-11-10T05:00:00Z\">11\u002F10\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-10-29T04:00:00Z\">10\u002F29\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftianjin-healthcare-medical-technology-co-ltd-736415-10292026\">Tianjin Healthcare Medical Technology Co., Ltd.\u003C\u002Fa>","","2026-11-17T01:02:03.701861+00:00","2026-11-17T01:02:49.409207+00:00",{"510k":31,"classification":32,"enforcement":33,"event":34,"event_backfill":35,"pma":36,"warning_letter":37},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]